Monroe Township, NJ. September 15, 2011—Green Hill Healthcare Communications, LLC, a privately held medical communications firm, announced today the launch of a ground-breaking first-of-its-kind journal, Personalized Medicine in Oncology (PMO),the official publication of the Global Biomarkers Consortium (GBC) in Oncology (www.globalbiomarkersconsortium.com).
PMO is a peer-reviewed journal serving the informational needs of oncologists related to precision medicine and the next generation of oncologic care. The first issue will be published in May 2012 and distributed at the American Society of Clinical Oncology Annual Meeting in Chicago, with six issues planned for 2012, transitioning to a monthly journal in 2013.
“The goal of Personalized Medicine in Oncology is to sensitize practitioners to the performance realities of new diagnostic and treatment discoveries and clarify molecular profiling technology as it relates to diagnostic, prognostic, and predictive medicine,” said Publisher Russell Hennessy.“PMO will feature diagnostic and clinical treatment information concerning these three root aspects of personalized medicine in oncology.”
“Personalized medicine is bringing out success in changing not just prognostic expectations, but actually changing the culture of medicine regarding prevention, diagnosis, and treatment. What’s more, the scale of success is immensely greater than anything we have accomplished in the past 30 or 40 years. I think we are in a position for the advances to be of much greater magnitude than we’ve been able to accomplish,” said PMO Board Member Edith Perez, MD, of the Mayo Clinic.
“It is imperative that the global community of oncologists/hematologists, oncology nurses, and oncology pharmacists understand and be able to incorporate all aspects of personalized medicine into cancer care. This includes the clinical application and prognostic precision of existing and emerging biomarkers that have been shown to be of value in guiding personalized therapy for their patients. As the official publication of the Global Biomarkers Consortium in Oncology, PMO will be the primary vehicle to augment the pivotal and contemporary education that will be presented at the GBC Annual Meeting held on March 9-11, 2012, in Orlando, Florida, as well as all of the educational activities of the GBC in Oncology,” said Pam Rattananont Ferris, Managing Director and CEO of Core Principle Solutions, the primary sponsor of the Global Biomarkers Consortium.
The oncology community has embraced the notion of personalized medicine, but with varying levels of sophistication. At the 2011 World Health Care Congress, a survey of physicians revealed that 98% of them acknowledged that personalized medicine is essential to their practice of medicine, but less than 20% stated satisfaction with their level of personal acumen. The gap between knowledge at the research level and application at the clinical level was stated loud and clear in the Institute of Medicine’s document “To Err Is Human,” which stated that on average it takes 17 years for new findings to become mainstream practice. While the pace of innovation uptake in cancer is faster than in medicine overall, the fact remains that the imperative for personalized medicine is that it be used, and used well, according to guidelines and every means of adoption of best practices.
Personalized Medicine in Oncology will address these issues in the hope of transforming the old model of stratified medicine into a new model ofpersonalized care in which all decisions and practices are tailored to the individual.
SECTION EDITORS
|
Breast Cancer Edith Perez, MD Mayo Clinic Jacksonville, FL |
Predictive Modeling Michael Kattan, PhD Case Western Reserve University Cleveland, OH |
Pathology David L. Rimm, MD, PhD Yale Pathology Tissue Services Yale University School of Medicine New Haven, Connecticut |
|
Hematologic Malignancies Gautam Borthakur, MD The University of Texas MD Anderson Cancer Center Houston, Texas |
Lung Cancer Vincent A. Miller, MD Memorial Sloan-Kettering Cancer Center Weill Cornell Medical College New York, New York |
Gastrointestinal Cancer Eunice Kwak, MD Massachusetts General Hospital Cancer Center Harvard Medical School Boston, Massachusetts |
|
Drug Development Igor Puzanov, MD Vanderbilt University Vanderbilt-Ingram Cancer Center Nashville, Tennessee |
Prostate Oliver Sartor, MD Tulane University New Orleans, Louisiana |
#######
About Green Hill Healthcare Communications, LLC
Green Hill Healthcare Communications, LLC, is a medical communications firm that specializes in creating informational products for underserved niches of the medical community. For more information about PMO or Green Hill Healthcare Communications, please contact Russell Hennessy (732-992-1888;
About Core Principle Solutions, LLC
Core Principle Solutions, LLC (CPS) (www.cps-me.com) is a privately owned global medical education company. We aspire to improve patient care by developing pivotal and contemporary medical education for healthcare professionals and patients worldwide. In order to fulfill this vision, we strive to create clinically applicable and innovative programs tailored for appropriate healthcare audiences by fostering the dialogue and collaboration among all stakeholders, including pharma/biotech, government, patient and public health associations, consumer goods organizations, healthcare practitioners, and patients. Our fundamental and underlying principle is to establish and maintain a deep respect for all individuals and the global community of which we are a part.
| CONTACT: |
Russell J. Hennessy Greenhill Healthcare Communications, LLC PHONE: 732-992-1888 E-MAIL: |
| CONTACT: |
John W. Hennessy Greenhill Healthcare Communications, LLC PHONE: 732-992-1886 E-MAIL: |
| CONTACT: |
Pam Rattananont Ferris, MPH Core Principle Solutions, LLC PHONE: 917-612-7104 E-MAIL: |